Challenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action

References

• Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608. doi:10.1001/jama.2013.13805
   PubMed Web of Science ®Google Scholar
• Dorsey E, George B, Leff B, Willis A. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80:1989–1996. doi:10.1212/WNL.0b013e318293e2ce
   PubMed Web of Science ®Google Scholar
• Deutschlander AB, Ross OA, Dickson DW, Wszolek ZK. Atypical parkinsonian syndromes: a general neurologist’s perspective. Eur J Neurol. 2018;25(1):41–58. doi:10.1111/ene.2018.25.issue-1
   Web of Science ®Google Scholar
• Levin J, Kurz A, Arzberger T, Giese A, Hoglinger GU. The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5):61–69. doi:10.3238/arztebl.2016.0061
   PubMed Web of Science ®Google Scholar
• Tsai RM, Boxer AL. Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol. 2014;34(2):225–234. doi:10.1055/s-00000071
   Web of Science ®Google Scholar
• Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156–171. doi:10.1093/brain/awn291
   PubMedGoogle Scholar
• Stamelou M, Hoeglinger GU. Atypical parkinsonism: an update. Curr Opin Neurol. 2013;26(4):401–405. doi:10.1097/WCO.0b013e3283632da6
   Web of Science ®Google Scholar
• Moretti DV. Available and future treatments for atypical parkinsonism. A systematic review. CNS Neurosci Ther. 2018;25:159–174.
   Web of Science ®Google Scholar
• Eschlbock S, Krismer F, Wenning GK. Interventional trials in atypical parkinsonism. Parkinsonism Relat Disord. 2016;22(Suppl 1):S82–S92. doi:10.1016/j.parkreldis.2015.09.038
   Google Scholar
• Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297–309. doi:10.1111/j.1468-1331.2008.02513.x
   PubMed Web of Science ®Google Scholar
• McFarland N. Diagnostic approach to atypical Parkinsonian syndromes. Continuum. 2016;22(4):1117–1142. doi:10.1212/CON.0000000000000348
   PubMedGoogle Scholar
• Litvan I, Lees PS, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord. 2016;31(5):644–652. doi:10.1002/mds.26512
   PubMed Web of Science ®Google Scholar
• Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999;56(1):90–94. doi:10.1001/archneur.56.1.90
   Google Scholar
• Mahajan A, Mari Z Patient Perspective in Multiple System Atrophy. International Parkinson and Movement Disorder Society 2018 International Congress; Hong Kong: International Parkinson and Movement Disorder Society; 2018.
   Google Scholar
• Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;34:7–14. doi:10.1016/j.parkreldis.2016.10.013
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(3):249–263. doi:10.1056/NEJMra1311488
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Gao W, Saleem TZ, et al. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One. 2012;7(11):e46327. doi:10.1371/journal.pone.0046327
   PubMed Web of Science ®Google Scholar
• Gerstenecker A, Duff K, Mast B, Litvan I, Group E-PS. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013;210(3):1205–1210. doi:10.1016/j.psychres.2013.08.045
   PubMed Web of Science ®Google Scholar
• Zhang LY, Cao B, Zou YT, et al. Depression and anxiety in multiple system atrophy. Acta Neurol Scand. 2018;137(1):33–37. doi:10.1111/ane.12804
   Web of Science ®Google Scholar
• Litvan I, Cummings J, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 1998;65:717–721. doi:10.1136/jnnp.65.5.717
   PubMed Web of Science ®Google Scholar
• McCrone P, Payan CA, Knapp M, et al. The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. PLoS One. 2011;6(9):e24369. doi:10.1371/journal.pone.0024369
   Web of Science ®Google Scholar
• Schmotz C, Richinger C, Lorenzl S. High burden and depression among late-stage idiopathic parkinson disease and progressive supranuclear palsy caregivers. J Geriatr Psychiatry Neurol. 2017;30(5):267–272. doi:10.1177/0891988717720300
   PubMed Web of Science ®Google Scholar
• Armstrong N, Schupf N, Grafman J, Huey ED. Caregiver burden in frontotemporal degeneration and corticobasal syndrome. Dement Geriatr Cogn Disord. 2013;36(5–6):310–318. doi:10.1159/000351670
   Web of Science ®Google Scholar
• National Investment Center for Seniors Housing & Care. Skilled Nursing Data Report: Key Occupancy & Revenue Trends; 2018.
   Google Scholar
• U.S. Food and Drug Administration. Developing products for rare diseases & conditions Silver Spring, MD; 2018. Available from: https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm.
   Google Scholar
• U.S. Food & Drug Administration. Fiscal Year 2019: Justification of Estimates for Appropriations Committees. Silver Spring, MD: Department of Health and Human Services; 2019.
   Google Scholar
• Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(Pt 6):1552–1565. doi:10.1093/brain/awm032
   PubMedGoogle Scholar
• Payan CA, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS–Parkinson plus scale. PLoS One. 2011;6(8):e22293. doi:10.1371/journal.pone.0022293
   Web of Science ®Google Scholar
• Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19(12):1391–1402. doi:10.1002/(ISSN)1531-8257
   Web of Science ®Google Scholar
• Hall DA, Forjaz MJ, Golbe LI, et al. Scales to assess clinical features of progressive supranuclear palsy: MDS task force report. Mov Disord Clin Pract. 2015;2(2):127–134. doi:10.1002/mdc3.12130
   Google Scholar